COMPARATIVE EVALUATION OF THE EFFICACY AND SAFETY OF TREATMENT USING ADALIMUMAB IN COMBINATION WITH METHOTREXATE AND METHOTREXATE MONOTHERAPY IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN COMBINATION WITH UVEITIS
https://doi.org/10.15690/vsp.v13i6.1204
Abstract
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and it is characterized by a primary lesion of the joints, organs and tissues with the formation of multiple organ failure of varying severity. The article describes the results of studying the efficacy and safety of adalimumab in combination with methotrexate (n = 26) and methotrexate monotherapy (n = 17) when treating the patients with polyarticular JIA and uveitis refractory to the basic immunosuppressive therapy. It was shown that the combination therapy induced the remission of arthritis in children with JIA in a shorter period of time. After 1 year, the disease remission was recorded in 42% of children in the treatment group and in 18% of children in the comparison group, the uveitis remission — in 26 (54%) of 48 eyes and 2 (7%) of 28 eyes with signs of lesions, respectively. It should be noted that adalimumab in combination with methotrexate was well tolerated and no serious adverse effects were recorded. Thus, the introduction of adalimumab in the treatment regimen of children with JIA and uveitis refractory to the basic immunosuppressive therapy allowed for the rapid disease remission while preserving the effect in a significant number of patients during the following year.
About the Authors
V. А. Kel’tsev
Samara State Medical University
Russian Federation
Russian Federation
L. I. Grebyonkina
Samara State Medical University
Russian Federation
Russian Federation
Ye. D. Moiseeva
Samara State Medical University
Russian Federation
Russian Federation
References
1. Textbook of paediatric rheumatology. 2nd edn. J. Cassidy, R. Petty (eds.). New York: Churchill Livigstone. 2002. 518 с.
2. Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. М.: Веди. 2007. 368 с.
3. Кельцев В. А. Ювенильный идиопатический артрит. Самара: Содружество. 2005. 214 с.
4. Кельцев В. А. Клиническая артрология (руководство для врачей). Самара: Содружество. 2008. 616 с.
5. Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294: 1671–1684.
6. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.
7. Schett G. Immune cells and mediators of inflammatory arthritis. Review. Autoimmunity. 2008; 41: 224–229.
8. Алексеева Е. И., Шахбазян И. Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоид- ного артрита. Аутоиммунные заболевания. М. 2002. 127 с.
9. Gabalawy H. S., Lipsky R. E. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2004; 4 (2): 297–301.
10. Foster H. E., Marshall N., MyersA., Ganser G. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003; 48: 767–775.
11. Lomater C., Gerloni V., Gattinara M., Vaize D., Woo P. Systemic onset juvenile rheumatoid arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000; 27: 491–496.
12. Minden K., Niewerth M., Listing J., Lesting G. Long-term outcome in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2392–2401.
13. Woo R., Wilkinson N. R., Prieur A. M. Ganser G. Open label phase 2 trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of efficacy of IL-6 receptor blocade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. 2005; 7: 1281–1288.
14. Feldman M., Brennan R., Maini R. N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397–440.
15. Насонов Е. Л. Фактор некроза опухоли a — новая мишень для противовоспалительной терапии ревматоидного артрита. Российский медицинский журнал. 2000; 8: 2–17.
16. Bradley J. R. TNF-mediated inflammatory disease. J. Pathol. 2008; 214: 149–160.
17. Ackermann C., Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Exp. Opin. Ther. Targets. 2007; 11: 1369–1384.
18. Ruperto N., Lovell D. J., Goodman S., Martini A. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): data over two years of treatment in a phase III study. 8thAnnual European League Against Rheumatism (EULAR 2007). Barcelona, Spain. 2007. Abstract THU0195.
19. Tynjala P., Kotaniemi K., Lindahl P., Becker G. C., Biom M. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. 2008; 47 (3): 339–344.
20. Biester S., Deuter C., Michels H., Becker G. C. Adalimumab in the therapy of uveitis in childhood. Brit. J. Ophthalmol. 2007; 91 (3): 319–324.
21. Алексеева Е. И., Валиева С. И., Бзарова Т. М., Лисицин А.О., Карагулян Н. А. Опыт применения адалимумаба у больного юношеским анкилозирующим спондилитом с поражением глаз. Вопросы современной педиатрии. 2009; 8 (1): 135–141.
22. Лисицин А. О., Алексеева Е. И., Бзарова Т. М., Валиева С. И., Гомахадзе А. М., Исаева К. Б. Опыт применения адалимума- ба у больной юношеским полиартритом с поражением глаз. Вопросы современной педиатрии. 2008; 7 (5): 115–120.
23. Wallace C. A., Ruperto N., Giannini E., Martini A. Preliminary criteria forclinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004; 31 (11): 2290–2294. 24. Hogan M. J., Kimura S. J., Thygeson P. Signs and symptoms of uveitis. Anterior uveitis. Am. J. Ophthalmol. 1959; 47 (5): 155–170.
Review
For citations:
Kel’tsev V.А., Grebyonkina L.I., Moiseeva Ye.D. COMPARATIVE EVALUATION OF THE EFFICACY AND SAFETY OF TREATMENT USING ADALIMUMAB IN COMBINATION WITH METHOTREXATE AND METHOTREXATE MONOTHERAPY IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN COMBINATION WITH UVEITIS. Current Pediatrics. 2014;13(6):60-66. (In Russ.) https://doi.org/10.15690/vsp.v13i6.1204
Views:
1030
Email this article 
